# BioCrossroads

> BioCrossroads is a VC fund backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Indianapolis, United States
- Total investments: 23
- Last investment: Oct 2022
- Lead investor: 9%
- Fund size: $9M
- Last fund: Oct 2018
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/biocrossroads
- X (Twitter): http://twitter.com/BioCrossroads
- Website: http://www.biocrossroads.com

BioCrossroads is a venture capital firm specializing in life sciences companies based in Indiana.

## Contacts

5 contacts available for BioCrossroads. Shizune tracks 3 team members at BioCrossroads. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biocrossroads?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 65% |
| Health Care | 11 | 48% |
| Therapeutics | 4 | 17% |
| Pharmaceutical | 4 | 17% |
| Life Science | 2 | 9% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 8 | 35% |
| Series A | 5 | 22% |
| Funding Round | 4 | 17% |
| Convertible Note | 2 | 9% |
| Venture - Series Unknown | 2 | 9% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Patricia Martin | President and CEO | 0 | https://shizune.co/investors/profile/patricia-martin-0aef |
| David Johnson | President and CEO | 0 | https://shizune.co/investors/profile/david-johnson-23 |
| Nora Doherty | Vice President of Finance | 1 | https://shizune.co/investors/profile/nora-doherty |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Gate Neurosciences | Gate Neurosciences is a healthcare company that offers neuroscience-related medical services. The company is developing the next-generation of targeted CNS therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. It was founded in 2018 and is headquartered in Carmel, IN, USA. | $25M | Venture - Series Unknown | Oct 05, 2022 |  |
| Lumavate | Lumavate is an enterprise platform for building progressive web apps (PWAs) at scale. Through the Lumavate platform, companies deliver highly-personalized mobile experiences throughout the entire customer journey. These mobile experiences drive increased adoption and long-term engagement via smart activation methods. Visit lumavate.com to learnmore. | $6M | Venture - Series Unknown | Jan 31, 2022 |  |
| Kovina Therapeutics | Kovina Therapeutics operates as a pre-clinical biotechnology company aims to discover a non-surgical, medical treatment for Human Papillomavirus (HPV) infections and cancers. | $2M | Seed | Oct 20, 2021 |  |
| Novosteo | Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created aproprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces. | $5.5M | Series A | Jan 13, 2021 |  |
| Sabanto | Sabanto is a farming-as-a-service performing row-crop field operations using low-cost autonomous systems. | $3M | Convertible Note | Dec 24, 2020 |  |
| MBX Biosciences | MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. | $34.6M | Series A | Jul 27, 2020 |  |
| Sexton Biotechnologies | Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research and product development, Sexton Biotechnologies will expand and scalecommercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction. | $5M |  | Sep 24, 2019 |  |
| Sabanto | Sabanto is a farming-as-a-service performing row-crop field operations using low-cost autonomous systems. | $2M | Seed | Aug 12, 2019 |  |
| Lumavate | Lumavate is an enterprise platform for building progressive web apps (PWAs) at scale. Through the Lumavate platform, companies deliver highly-personalized mobile experiences throughout the entire customer journey. These mobile experiences drive increased adoption and long-term engagement via smart activation methods. Visit lumavate.com to learnmore. | $3M |  | Jun 12, 2019 |  |
| Scioto Biosciences | Scioto Biosciences is a developer of Activated Bacterial Therapeutics (ABT) platform intended to deliver live bacteria to the gut. The company is developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics, enabling medical practitioners to advance healing through microbiome therapeutics. |  | Series A | May 21, 2018 |  |

10 of 23 investments shown.

## Co-investors
- [Elevate Ventures](https://shizune.co/investors/profile/elevate-ventures) — VC Fund, 4 deals together
- [IU Ventures](https://shizune.co/investors/profile/iu-ventures) — VC Fund, 3 deals together
- [4G Ventures](https://shizune.co/investors/profile/4g-ventures) — VC Fund, 2 deals together
- [Cavallo Ventures](https://shizune.co/investors/profile/cavallo-ventures) — VC Fund, 2 deals together
- [Collina Ventures](https://shizune.co/investors/profile/collina-ventures) — VC Fund, 2 deals together
- [DCVC Bio](https://shizune.co/investors/profile/dcvc-bio) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does BioCrossroads invest in?

BioCrossroads invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BioCrossroads?

Public channels for BioCrossroads include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioCrossroads?

The team at BioCrossroads includes Patricia Martin (President and CEO), David Johnson (President and CEO) and Nora Doherty (Vice President of Finance). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co